Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)

TPEX:4186 Revenue

In the year 2025, Taiwan Advance Bio-Pharmaceutical had annual revenue of 364.79M TWD with 3.00% growth. Taiwan Advance Bio-Pharmaceutical had revenue of 169.35M in the half year ending June 30, 2025, with 31.46% growth.

• Revenue: 364.79M
• Revenue Growth: +3.00%
• P/S Ratio: 2.46
• Revenue / Employee: 2.21M
• Employees: 165
• Market Cap: 896.40M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	364.79M	10.62M	3.00%
Dec 31, 2024	354.17M	38.19M	12.09%
Dec 31, 2023	315.98M	-2.25M	-0.71%
Dec 31, 2022	318.24M	74.87M	30.77%
Dec 31, 2021	243.36M	7.79M	3.31%

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2025

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

May 29, 2026

Data Sources Report a data error